Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range.
May 1, 2026
- How bots could help revive democracy
- ‘Profoundly distressing’: record number of deaths in custody and police operations in NSW | Deaths in custody
- Adani Group Unveils Restructuring as It Positions for Growth
- On May Day, Gaza’s workers find whatever source of income they can | Israel-Palestine conflict News
Back To Top